European regulators have validated Rigel Pharmaceuticals’ application to market fostamatinib for adult chronic immune thrombocytopenia (ITP).
News
Carrick licenses targeted ovarian cancer drug from BTG
Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.
PharmaTimes International Clinical Researcher of the Year 2019 is open for entry
The PharmaTimes International Clinical Researcher of the Year competition is now open for entry, flying the flag for excellence in global clinical research for its 20th year.
Janssen files nasal spray for depression
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
ABPI tells MPs Brexit deal on medicines regulation ‘urgently needed’
Pharmaceutical companies “are doing everything in their power” to minimise disruption to the supply of medicines should the UK leave the EU under a ‘no-deal’ scenario, but a deal is urgently needed to fully protect patients, MPs have been told.
Healthcare communications at its best
The Communications Team of the Year Awards will take place at The Tower Hotel, London on Thursday 15 November, alongside Marketer of the Year and the all-new Sales Awards.
Celebrating sales and marketing excellence
Such is the link between the two disciplines, Marketer of the Year will celebrate its 25th anniversary at The Tower Hotel, London on Thursday 15 November, alongside the all-new Sales Awards.
XLH patients to get routine access to first new therapy in 30 years
For the first time in more than 30 years children and young adults in England and Wales with the rare bone disorder XLH will have access to a new treatment option via the NHS.
Novartis crizanlizumab shows promise in sickle cell anaemia
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.
Affimed shares plunge on trial death
Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death.
Diurnal shares plummet on trial failure
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
The PharmaTimes Medical & Scientific Excellence Awards – could it be you?
Do you have a passion for medical information? Could you be among the first in the field to win at the hotly anticipated PharmaTimes Medical & Scientific Excellence Awards?
Novartis files MS drug siponimod in EU and US
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
New UK biopharma Sitryx launches with $30m fundraising
New UK biopharmaceutical group Sitryx has launched operations with $30 million to help it develop disease-modifying therapeutics in immunometabolism.
Mixed data for Xencor’s SLE drug
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
